b-022

B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.

Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

Dynamin-related GTPase DRP1 partial inhibitor (IC50 = 1.2 μM). Selective for DRP1 over other dynamin-related GTPases, OPA1 and DYN1. Increases mitochondrial DNA levels in mfn1- knockout MEFs deficient in mitochondrial fusion. Mallat et al (2018) Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1. Biochem.Biophys.Res.Commun. 499 556 PMID:29601815

BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. It inhibits the phosphorylation of IGF-1 and IGF-2-induced IGF-1R and its downstream substrates. BIIB022 is applicable for research in lung cancer, pancreatic cancer, and colon cancer. The recommended isotype control is Human IgG4 kappa, Isotype Control.

Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).

Orelabrutinib (Standard) is a reference standard for research and analysis in studies involving Orelabrutinib. Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).